Browse the evidence

Understanding factors associated with paraspinal muscle atrophy can help develop personalized rehabilitation protocols for postoperative recovery.

Practitioners can use these findings to tailor rehabilitation strategies for better recovery outcomes.

In patients with cardiovascular disease and diabetes mellitus, lower-extremity muscle strength is significantly associated with peak oxygen uptake (VO 2peak).

Practitioners should focus on improving lower-extremity muscle strength in patients with CVD and DM to enhance exercise capacity.

The interaction between diabetes mellitus and lower-extremity muscle strength significantly affects exercise capacity.

Understanding the interaction between diabetes and muscle strength can help tailor exercise programs for better outcomes.

Continuous glucose monitoring (CGM) may be a useful tool for promoting dietary awareness and self-management among non-diabetic athletes.

Practitioners may consider using CGM to enhance dietary management in trained athletes.

Regular follow-up is crucial for tracking outcomes and evaluating evolving aesthetic needs in GLP-1 weight loss patients.

Practitioners should implement regular follow-ups to ensure effective treatment and satisfaction.

High cardiorespiratory fitness is associated with 0.08 to 0.13 standard deviation better global cognitive function, executive function, and attention.

Encouraging higher cardiorespiratory fitness may improve cognitive health in individuals with type 2 diabetes.

GLP-1RA users had a lower risk of dementia (HR, 0.63; 95% CI, 0.50-0.81) compared to other antidiabetic drug users.

Practitioners may consider GLP-1RAs as a treatment option for reducing dementia risk in this population.

Allodynia was observed in 4 patients associated with dose escalation of semaglutide.

Clinicians should be aware of the potential for allodynia in patients taking semaglutide.

Tirzepatide dose-dependently reduced voluntary alcohol consumption and prevented binge and relapse-like drinking.

Tirzepatide may help in managing alcohol use disorder by reducing consumption and preventing relapse.

Environmental cues such as chronic cold exposure, exercise, and caloric restriction potentiate adipocyte browning.

Incorporating cold exposure, exercise, and caloric restriction may enhance browning and its benefits.

GLP-1 receptor agonists can induce psychiatric side effects such as increased impulsivity, dysphoria, and aggression.

Physicians should be cautious of potential psychiatric side effects when prescribing GLP-1 RAs.

There may be a relationship between GLP-1 receptor agonists and mood.

Further investigation is warranted to understand the mood-related effects of GLP-1 RAs.

GLP-1 RAs influence blood pressure through mechanisms such as sympathetic nervous modulation, vasodilation, and diuretic effects.

Understanding these mechanisms can help in tailoring hypertension treatments.

Specific warm-up (SWU) protocols are similar to no warm-up (CON) regarding resistance training (RT) performance and perceptual responses.

Practitioners may consider skipping warm-up protocols to save time without compromising performance.

The comparison of 1SET and 2SET to CON indicated negligible to small potential differences for all outcomes.

The differences in warm-up protocols may not be significant enough to warrant changes in practice.

Posterior probabilities of SWU conditions being superior to CON remained relatively low for the bench press and 45° leg press.

There is little evidence to support the necessity of specific warm-up protocols for improving performance.

GLP-1 agonists may decrease sexual desire through increased serotonergic activity at the 5-HT2C receptor.

Clinicians should consider the potential impact of GLP-1 agonists on sexual desire when prescribing these medications.

The effects of GLP-1 agonists on sexual desire may be overlooked due to competing influences.

Awareness of these competing influences is crucial for healthcare providers managing patients on GLP-1 agonists.

GLP-1RAs provide direct neurovascular protection by stabilizing the blood-brain barrier and modulating neuroinflammation.

GLP-1RAs may be beneficial in protecting brain health and reducing stroke risk.

The findings suggest potential neurobehavioral benefits associated with incretin-based therapies (IBTs) in a high-risk population.

These findings may guide clinicians in selecting appropriate treatments for patients at risk of AUD post-surgery.

A neural network achieved an overall accuracy of 72.5% in predicting 12-month weight loss from baseline characteristics.

Utilizing neural network models may enhance the prediction of weight loss outcomes in clinical settings.

Patients with less-collapsible upper airways and low loop gain at baseline may be more likely to see improvements in their OSA severity after surgery.

Identifying patients with specific baseline characteristics may help tailor treatment approaches for OSA.

Tirzepatide is associated with a lower risk of dementia versus semaglutide (HR 0.69, 95% CI 0.48-0.99, p = 0.04).

Practitioners may consider tirzepatide as a potentially safer option for reducing dementia risk in patients with type 2 diabetes.

Patients with obesity face multiple barriers to cardiac rehabilitation participation and adherence.

Addressing these barriers is crucial for improving CR participation rates among obese patients.